Results for Durvalumab in the Second-Line Treatment of NSCLC

July 13, 2017
Martin Gutierrez, MD

Martin Gutierrez, MD, director, drug discovery/phase I unit, medical oncologist, thoracic and gastrointestinal oncology, John Theurer Cancer Center, discusses results for durvalumab (Imfinzi) for the treatment of non-small cell lung cancer.